10.1126/science.134.3483.943 46 HolscherC
In the SURPASS trials, tirzepatide demonstrated superior HbA1c reduction compared to placebo, insulin, and other GLP-1 receptor agonists including semaglutide 1 mg weekly (SURPASS-2)
However, always consult a healthcare professional before starting any treatment
Methylmalonyl-CoA is a competitive inhibitor of malonyl-CoA in fatty acid biosynthesis as well as being able to substitute for malonyl-CoA in any fatty acid biosynthesis that may occur
Risk of nonarteritic anterior ischemic optic neuropathy (NAION) in patients prescribed semaglutide Novo Nordisk A new observational study reported for the first time a potential link between Novo Nordisks GLP-1 drugs Ozempic and Wegovy and an eye condition that can cause vision loss
The challenging work of actual nutritional improvement and other lifestyle improvements must also happen to improve a persons health and longevity. Published 8/19/2024 About the Expert Heidi Prather, DO, is an Attending Physiatrist at HSS and leads the HSS Lifestyle Medicine Program
